These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39048052)

  • 1. Accumulation of alkyl-lysophosphatidylcholines in Niemann-Pick disease type C1.
    Mishra S; Kell P; Scherrer D; Dietzen DJ; Vite CH; Berry-Kravis E; Davidson C; Cologna SM; Porter FD; Ory DS; Jiang X
    J Lipid Res; 2024 Aug; 65(8):100600. PubMed ID: 39048052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease.
    Bradbury A; Bagel J; Sampson M; Farhat N; Ding W; Swain G; Prociuk M; O'Donnell P; Drobatz K; Gurda B; Wassif C; Remaley A; Porter F; Vite C
    J Pharmacol Exp Ther; 2016 Aug; 358(2):254-61. PubMed ID: 27307499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
    Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling.
    Fan M; Sidhu R; Fujiwara H; Tortelli B; Zhang J; Davidson C; Walkley SU; Bagel JH; Vite C; Yanjanin NM; Porter FD; Schaffer JE; Ory DS
    J Lipid Res; 2013 Oct; 54(10):2800-14. PubMed ID: 23881911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β metabolism in Niemann-Pick C disease models and patients.
    Mattsson N; Olsson M; Gustavsson MK; Kosicek M; Malnar M; Månsson JE; Blomqvist M; Gobom J; Andreasson U; Brinkmalm G; Vite C; Hecimovic S; Hastings C; Blennow K; Zetterberg H; Portelius E
    Metab Brain Dis; 2012 Dec; 27(4):573-85. PubMed ID: 22935999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease.
    Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Vite CH; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Bodamer O; Wang RY; Plummer E; Schaffer JE; Ory DS; Jiang X
    Mol Genet Metab; 2020 Apr; 129(4):292-302. PubMed ID: 32033912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.
    Lopez AM; Terpack SJ; Posey KS; Liu B; Ramirez CM; Turley SD
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):780-7. PubMed ID: 25115571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of cholesterol homeostasis by 2-hydroxypropyl-β-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice.
    Peake KB; Vance JE
    J Biol Chem; 2012 Mar; 287(12):9290-8. PubMed ID: 22277650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC3 Immunostaining in the Inferior Olivary Nuclei of Cats With Niemann-Pick Disease Type C1 Is Associated With Patterned Purkinje Cell Loss.
    Gurda BL; Bagel JH; Fisher SJ; Schultz ML; Lieberman AP; Hand P; Vite CH; Swain GP
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):229-245. PubMed ID: 29346563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.
    Nicoli ER; Al Eisa N; Cluzeau CV; Wassif CA; Gray J; Burkert KR; Smith DA; Morris L; Cologna SM; Peer CJ; Sissung TM; Uscatu CD; Figg WD; Pavan WJ; Vite CH; Porter FD; Platt FM
    PLoS One; 2016; 11(3):e0152007. PubMed ID: 27019000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.
    Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD
    Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1.
    Cluzeau CV; Watkins-Chow DE; Fu R; Borate B; Yanjanin N; Dail MK; Davidson CD; Walkley SU; Ory DS; Wassif CA; Pavan WJ; Porter FD
    Hum Mol Genet; 2012 Aug; 21(16):3632-46. PubMed ID: 22619379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1.
    Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Wang RY; Movsesyan N; Plummer E; Schaffer JE; Ory DS; Jiang X
    Mol Genet Metab; 2020 Dec; 131(4):405-417. PubMed ID: 33257258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life.
    Ramirez CM; Liu B; Taylor AM; Repa JJ; Burns DK; Weinberg AG; Turley SD; Dietschy JM
    Pediatr Res; 2010 Oct; 68(4):309-15. PubMed ID: 20581737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.
    Calias P
    Curr Pharm Des; 2017; 23(40):6231-6238. PubMed ID: 29065825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.
    Cougnoux A; Drummond RA; Collar AL; Iben JR; Salman A; Westgarth H; Wassif CA; Cawley NX; Farhat NY; Ozato K; Lionakis MS; Porter FD
    Hum Mol Genet; 2018 Jun; 27(12):2076-2089. PubMed ID: 29617956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-ß-cyclodextrin.
    Palladino G; Loizzo S; Fortuna A; Canterini S; Palombi F; Erickson RP; Mangia F; Fiorenza MT
    Orphanet J Rare Dis; 2015 Oct; 10():133. PubMed ID: 26458950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Proteomics Reveals miR-155 as a Novel Indicator of Liver and Spleen Pathology in the Symptomatic Niemann-Pick Disease, Type C1 Mouse Model.
    Pergande MR; Cougnoux A; Rathnayake RAC; Porter FD; Cologna SM
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30870990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.